News | June 04, 2015

Beaumont Hospital Offers New Device for Right-Side Heart Failure Patients

Seventy-two-year-old patient becomes first in Michigan to receive Impella RP pump

Beaumont Hospital Royal Oak, Impella RP, right-side heart failure, Abiomed

June 4, 2015 - Beaumont Hospital, Royal Oak is one of the first centers in the United States to use a new minimally invasive heart pump designed to provide temporary support for patients with severe right-side heart failure.

The Impella RP device provides circulatory assistance for up to 14 days for patients who develop severe right heart failure following heart attack, open-heart surgery, heart transplantation or left ventricular assist device implantation.

Beaumont, Royal Oak interventional cardiologist Ivan Hanson, M.D., and heart surgeon Jeffrey Altshuler, M.D., performed Michigan's first commercial implant of the new device on March 26, in a 72-year-old man from Detroit.

"The Impella RP is a tremendous advance for patients who develop acute right heart failure," says Simon Dixon, M.D., chair of cardiovascular medicine, Beaumont Health System. "Until now, there have been few options for these critically ill patients other than a surgically implanted ventricular assist device. This revolutionary technology provides a minimally invasive approach to support and bridge these patients until the right heart has had time to recover."

According to James Goldstein, M.D, a Beaumont cardiologist and pioneer in the field of heart attack involving the right heart, "This device has the potential to stabilize a patient in a life-threatening situation and give them hope for recovery without further interventions."

The Impella RP is implanted in the right side of the patient's heart via a very small incision in the femoral vein in the leg. Once positioned, the heart pump draws blood from the inferior vena cava, the major vein that drains to the heart, into the main pulmonary artery in the lungs, resting the patient's right pump, or ventricle.

The device can only be used for patients in the hospital and is removed when the physician determines that the right side of the patient's heart has recovered.

In clinical research studies, the Impella RP helped improve heart function in patients by allowing their right heart to rest and recover. Some patients became candidates for permanent heart pumps. Others were able to avoid major operations such as open-heart surgery. In a U.S. Food and Drug Administration-approved clinical trial of the device conducted in 2014, approximately 3 out of 4 patients treated with the device survived for either 30 days or to hospital discharge. The device was successfully implanted in 9 out of 10 patients.

The Impella RP was developed by Abiomed Inc., based in Danvers, Massachusetts.

For more information:

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Wearable monitors create patient generated health data, PGHD, that can help prevent acute care episodes in heart failure.

Wearable monitoring devices may offer a new tool to help prevent acute care episodes in heart failure.

Feature | Heart Failure| July 25, 2017 | Lola Koktysh
Despite their best efforts, many patients tend to develop heart failure after an acute event (e.g., a heart attack or
Overlay Init